Companies › PolTREG
2 active drug programs in 2 registered trials: 2 Phase 2; Metabolic and endocrine; next expected readout Dec 2032.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| ex vivo expanded CD4+CD25+CD127- regulatory T cells (Tregs) Ex vivo expanded regulatory T cell therapy | CD4, CD25, IL2RA | Phase 2 | Presymptomatic Diabetes Type 1 (Stage 1) | Dec 2032 |
| rituximab B-lymphocyte antigen CD20 binding agent | MS4A1 | Phase 2 | Presymptomatic Diabetes Type 1 (Stage 1) | Dec 2032 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06688331 | ex vivo expanded CD4+CD25+CD127- regulatory T cells (Tregs) | Phase 2 | Presymptomatic Diabetes Type 1 (Stage 1) | Metabolic and endocrine | Dec 2032 |
| NCT06688331 | rituximab | Phase 2 | Presymptomatic Diabetes Type 1 (Stage 1) | Metabolic and endocrine | Dec 2032 |
Roche Regeneron Pharmaceuticals Biocad Acerta Pharma GSK TaiMed Biologics Nektar Therapeutics Mural Oncology GI Innovation Synthekine
Actimed Therapeutics Verdiva Bio Dev Protalix Veru Skye Bioscience
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.